People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase 2 clinical trials may continue to use Anavex Life Sciences‘ investigational oral therapy at their doctor’s request. Under a special access scheme, the Therapeutic Goods Administration (TGA) — a part of the Australian Government Department of Health — allowed for compassionate use based on safety findings and early evidence of benefit in these clinical studies. A larger Phase 3 trial in early Alzheimer’s…
You must be logged in to read/download the full post.
The post Patients in Australian Trials of Anavex 2-73 May Continue Using Therapy, Agency Says appeared first on BioNewsFeeds.